(19)
(11) EP 1 613 328 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.06.2009 Bulletin 2009/24

(45) Mention of the grant of the patent:
18.03.2009 Bulletin 2009/12

(21) Application number: 04724599.8

(22) Date of filing: 31.03.2004
(51) International Patent Classification (IPC): 
A61K 31/55(2006.01)
 A61P 25/14(2006.01)
(86) International application number:
PCT/EP2004/003418
(87) International publication number:
WO 2004/087166 (14.10.2004 Gazette 2004/42)

(54)

USE OF CARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AGITATION IN DEMENTIA PATIENTS

VERWENDUNG VON CARBAMAZEPINDERIVATEN ZUR BEHANDLUNG VON AGITATIO IN DEMENSPATIENTEN

UTILISATION DE DERIVES DE CARBAMAZEPINE DANS LE TRAITEMENT DE L'AGITATION CHEZ DES PATIENTS ATTEINTS DE DEMENCE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30) Priority: 01.04.2003 US 459338 P

(43) Date of publication of application:
11.01.2006 Bulletin 2006/02

(73) Proprietors:
  • NOVARTIS AG
    4056 Basel (CH)
    Designated Contracting States:
    BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • SHUA-HAIM, Joshua
    Eatontown, NJ 07724 (US)
  • MARTENYI, Ferenc
    H-1061 Budapest (HU)

(74) Representative: Harrison Goddard Foote 
Belgrave Hall Belgrave Street
Leeds LS2 8DD
Leeds LS2 8DD (GB)


(56) References cited: : 
EP-A- 0 751 129
 WO-A-02/098418
   
  • AMBROSIO A F ET AL: "MECHANISMS OF ACTION OF CARBAMAZEPINE AND ITS DERIVATIVES, OXCARBAZEPINE, BIA 2-093, AND BIA 2-024" NEUROCHEMICAL RESEARCH, PLENUM PRESS, NEW YORK, US, vol. 27, no. 1/2, February 2002 (2002-02), pages 121-130, XP009022844 ISSN: 0364-3190
  • BENES J ET AL: "Anticonvulsant and Sodium Channel-Blocking Properties of Novel 10,11-Dihydro-5H-dibenz[b,f]azepine-5-carb oxamide Derivatives" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, 1999, pages 2582-2587, XP002206156 ISSN: 0022-2623
  • LEMKE MATTHIAS R: "Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics" JOURNAL OF CLINICAL PSYCHIATRY, vol. 56, no. 8, 1995, pages 354-357, XP000903495 ISSN: 0160-6689
  • FITZGERALD BRIAN J ET AL: "Elevation of carbamazepine-10,11-epoxide by quetiapine." PHARMACOTHERAPY, vol. 22, no. 11, November 2002 (2002-11), pages 1500-1503, XP009033502 ISSN: 0277-0008
  • SHUA-HAIM J: "Oxcarbazepine in the management of behavioral agitation in community-dwelling patients with Alzheimer's disease: An open-label Study." EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 13, no. Supplement 4, September 2003 (2003-09), page S434, XP002288071 & 16TH CONGRESS OF THE EUROPEAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY; PRAGUE, CZECH REPUBLIC; SEPTEMBER 20-24, 2003 ISSN: 0924-977X
  • S.C. SCHACHTER: "Oxcabazepine: current status and clinical applications" EXP. OPIN. INVEST. DRUGS, vol. 8, no. 7, 1999,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).